Arginine sodium | 15690-14-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Arginine sodium
• CAS: 15690-14-9
• 化学式: C6H14N4NaO2
• 分子量: 197.19
• InChiKey: ROHHYGMDHXYPJS-WCCKRBBISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.93
• 重原子数：
  13
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  128
• 氢给体数：
  4
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  sildenafil hydrochloride 、 Arginine sodium 在 氯化钠 、 甲醇 、 sildenafil-L-arginine complex 作用下， 以 乙醇 、 水 为溶剂， 反应 1.0h， 以The Sildenafil-L-Arginine complex salt (10.8 g) is obtained的产率得到sildenafil-L-arginine complex
  参考文献：
  名称：

  Processes for preparing amine salts of sildenafil-analogues and use thereof

  摘要：

  一系列胺盐包括公式（I）和公式（III）的结构已经提供。在公式I或公式（III）中，R1、Ra和RX如规范中所定义。本发明披露的胺络合盐具有前药活性形式和各种药物功能的特点。

  公开号：

  US08497370B2

文献信息

• PROCESSES FOR PREPARING AMINE SALTS OF SILDENAFIL-ANALOGUES AND USE THEREOF
  申请人：Chen Ing-Jun

  公开号：US20120108604A1

  公开（公告）日：2012-05-03

  A series of amine salts including a structure of formula (I) and formula (III) have provided. In formula I or formula (III), R 1 , R a and RX are as defined in the specification. The amine complex salts disclosed in the present invention are characterized in a pro-drug active form and various pharmaceutical function.

  提供了一系列包括公式(I)和公式(III)结构的胺盐。在公式I或公式(III)中，R1、Ra和RX如说明书中所定义。本发明公开的胺络合盐具有前药活性形式和多种药理功能。
• Plasminogen Activator Inhibitor-1 Inhibitor
  申请人：Miyata Toshio

  公开号：US20120022080A1

  公开（公告）日：2012-01-26

  The present invention provides a novel compound having plasminogen activator inhibitor-1 inhibitory activity, and an inhibitor of PAI-1 comprising the compound as an active ingredient. The present invention also provides a pharmaceutical composition having an inhibitory action on PAI-1 activity and being efficacious in the prevention and treatment of various diseases whose onset is associated with PAI-1 activity.

  本发明提供了一种具有纤溶酶原激活物抑制剂-1抑制活性的新化合物，以及包括该化合物作为活性成分的PAI-1抑制剂。本发明还提供了一种对PAI-1活性具有抑制作用且在预防和治疗与PAI-1活性相关的各种疾病方面有效的药物组合物。
• [EN] COMPOSITION CONTAINING ARTESUNATE<br/>[FR] COMPOSITION CONTENANT DE L'ARTÉSUNATE
  申请人：ZHAO MING

  公开号：WO2017124045A1

  公开（公告）日：2017-07-20

  The present disclosure provides a composition of artesunate, a process of preparing the same, and a method of treatment.

  本公开提供了一种青蒿素的组成，其制备过程以及治疗方法。
• PHARMACEUTICAL FORMULATION CONTAINING ANGIOTENSIN-II RECEPTOR BLOCKER
  申请人：Kim Sung Wuk

  公开号：US20110117194A1

  公开（公告）日：2011-05-19

  The present invention provides a pharmaceutical formulation containing an angiotensin-II receptor blocker and a release-control material as a pharmacologically active ingredient and a pharmaceutical formulation comprising an immediate-release compartment and an extended-release compartment. The immediate-release compartment contains an agent as a pharmacologically active ingredient for preventing and inhibiting hepatitis and the extended-release compartment has an angiotensin-II receptor blocker as a pharmacologically active ingredient. The formulation of the present invention maximizes the effectiveness on pharmacologically and clinically lowering blood pressure and preventing complications when taking the formulation, helps to avoid interaction with a drug which is metabolized by the same enzyme in the liver, and prevents and inhibits the incidence of drug-induced hepatitis which is caused by drug administration for a long time.

  本发明提供一种药物制剂，其包含一种血管紧张素II受体拮抗剂和一种释放控制材料作为药理活性成分，以及一种包括即时释放隔间和延时释放隔间的药物制剂。即时释放隔间含有一种药理活性成分，用于预防和抑制肝炎，而延时释放隔间则含有一种血管紧张素II受体拮抗剂作为药理活性成分。本发明的制剂在服用时最大程度地提高了药理和临床降低血压、预防并发症的有效性，有助于避免与同样在肝脏中代谢的药物发生相互作用，并预防和抑制由于长期用药引起的药物性肝炎的发生。
• Water-soluble mesoporphyrin compounds and methods of preparation
  申请人：——

  公开号：US20040097481A1

  公开（公告）日：2004-05-20

  Water soluble tin mesoporphyrin compounds are described. Methods of preparation of water soluble metal mesoporphyrin compounds and pharmaceutical preparations are also described.

  本文描述了可溶于水的锡中间体卟啉化合物。同时还描述了制备水溶性金属卟啉化合物和制药制剂的方法。